Nektar Therapeutics
NKTR
350 hedge funds and large institutions have $5.48B invested in Nektar Therapeutics in 2019 Q1 according to their latest regulatory filings, with 41 funds opening new positions, 140 increasing their positions, 109 reducing their positions, and 31 closing their positions.
32% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 31
28% more repeat investments, than reductions
Existing positions increased: 140 | Existing positions reduced: 109
2% more funds holding
Funds holding: 343 → 350 (+7)
1% more capital invested
Capital invested by funds: $5.41B → $5.48B (+$66.7M)
0.11% less ownership
Funds ownership: 6.36% → 6.24% (-0.11%)
42% less call options, than puts
Call options by funds: $28.1M | Put options by funds: $48.5M
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$87.7M |
| 2 |
BB
BB Biotech
Schaffhausen,
Switzerland
|
+$25.3M |
| 3 |
D.E. Shaw & Co
New York
|
+$16.7M |
| 4 |
JP Morgan Chase
New York
|
+$16.2M |
| 5 |
State Street
Boston,
Massachusetts
|
+$12.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$219M |
| 2 |
Morgan Stanley
New York
|
-$22.7M |
| 3 |
BlackRock
New York
|
-$18.3M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$16.3M |
| 5 |
Voloridge Investment Management
Jupiter,
Florida
|
-$10.6M |
NKTR Hedge Fund Activity: Q1 2019 in Review
350 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Nektar Therapeutics (NKTR) for Q1 2019, worth a combined $5.48B — up 1.2% from $5.41B a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new NKTR positions and 31 closed out — a net gain of 10 holders — while 140 added to existing stakes and 109 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $87.7M. The largest seller was Fidelity Investments, cutting an estimated $219M.
- 350 institutional investors held Nektar Therapeutics (NKTR) as of Q1 2019, up from 343 in Q4 2018.
- Funds reported $5.48B of Nektar Therapeutics stock for Q1 2019, up 1.2% quarter-over-quarter.
- 41 funds opened new Nektar Therapeutics positions in Q1 2019 and 31 closed out, a net change of +10 holders.
- The largest Nektar Therapeutics buyer in Q1 2019 was Wellington Management Group, an estimated $87.7M added.
- The largest Nektar Therapeutics seller in Q1 2019 was Fidelity Investments, an estimated $219M sold.
Based on aggregated 13F filings for Q1 2019.